{"filing":{"accession_number":"0001437749-26-019478","cik":"0000863894","ticker":"VERU","company_name":"VERU INC.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"veru20260601_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/863894/000143774926019478/veru20260601_8k.htm"},"events":[{"id":6884,"run_id":6033,"accession_number":"0001437749-26-019478","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Veru Inc. entered into a clinical supply agreement with Novo Nordisk on June 2, 2026, to support the Phase 2b PLATEAU study combining enobosarm with Wegovy® (semaglutide). While this is a material collaboration that advances the Company's clinical development program and grants Novo Nordisk a right of first negotiation for future combination development, it does not fit neatly into the standard M\u0026A, partnership, or licensing categories. The agreement is primarily a clinical supply arrangement rather than a traditional acquisition, disposition, or material licensing deal, making \"other_material\" the most appropriate classification for this strategic clinical collaboration.","company_name":"VERU INC.","ticker":"VERU","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4426,"accession_number":"0001437749-26-019478","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Veru Inc. entered into a clinical supply agreement with Novo Nordisk on June 2, 2026, to support the Phase 2b PLATEAU study combining enobosarm with Wegovy® (semaglutide). While this is a material collaboration that advances the Company's clinical development program and grants Novo Nordisk a right of first negotiation for future combination development, it does not fit neatly into the standard M\u0026A, partnership, or licensing categories. The agreement is primarily a clinical supply arrangement rather than a traditional acquisition, disposition, or material licensing deal, making \"other_material\" the most appropriate classification for this strategic clinical collaboration.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:18:47.094240+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4426,"accession_number":"0001437749-26-019478","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Veru Inc. entered into a clinical supply agreement with Novo Nordisk on June 2, 2026, to support the Phase 2b PLATEAU study combining enobosarm with Wegovy® (semaglutide). While this is a material collaboration that advances the Company's clinical development program and grants Novo Nordisk a right of first negotiation for future combination development, it does not fit neatly into the standard M\u0026A, partnership, or licensing categories. The agreement is primarily a clinical supply arrangement rather than a traditional acquisition, disposition, or material licensing deal, making \"other_material\" the most appropriate classification for this strategic clinical collaboration.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:18:47.094240+00:00","company_name":"VERU INC.","ticker":"VERU","filing_date":"2026-06-04"}]}